Phase 3 N=80 Role of Propolis Paste in Preventing Pain After Root Canal Treatment.
Pain, Postoperative
Primary: Pain Intensity Measure: Visual Analogue Pain Scale — 11.8; 8.8; 9.4; 10.3 score on a scale — p=0.329
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=184 Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: Inspiratory Capacity at Rest Measured at 60 Minutes Post-dose — 1.875; 1.990 Litre (L) — p=<0.001
Phase 3 N=300 Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A
Infections, Streptococcal
Primary: Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes for Subjects Receiving Synflorix Vaccine Co-administered With Tritanrix-HepB/Hib and Polio Sabin…
Phase 3 N=106 A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer
Radiotherapy Induced Mucositis · Head and Neck Cancer
Primary: Severity of Mucositis According to the Radiation Therapy Oncology Group (RTOG) for Patients Who Had at Least One Mucositis Assessment — 14; 18 Participants
Phase 3 N=227 Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
Arthralgia · Breast Cancer · Hot Flashes
Primary: Change in Item #3 (Average) of the Brief Pain Inventory (BPI) Average Pain From Baseline to Month 3 — -1.9; -2.0 score on a scale — p=0.4952
Phase 3 N=85 SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.
Transient Insomnia
Primary: Total Sleep Time (TST) — 401.82; 404.83; 397.28; 307.38 minutes
Phase 3 N=156 PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD
ADHD
Primary: Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP)-Combined Scores During the Full-Day Laboratory Classroom — 11.4; 18.2 score on SKAMP-C — p=<0.0001
Phase 3 N=25 Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy
Bladder Carcinoma
Primary: Patient Total Equivalent Analgesic Requirement (Morphine Equivalents) — 297.65; 396.16 Total oral morphine equivalents in mg
Phase 3 N=448 A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD
Type 2 Diabetes Mellitus, CKD and Albuminuria
Primary: Adjusted Mean Change From Baseline in Glycosylated Haemoglobin (HbA1c): Comparison of Dapagliflozin 10 mg Plus Saxagliptin 2.5 mg and Placebo at Week 24 — -0.85; -0.27…
Phase 3 N=91 Contact Lenses With New UV-blocker Manufactured With Different Techniques
Correction of Refraction Error · Attenuation of Bright Light
Primary: Overall Comfort Score — 61.49; 67.27 Units on a scale
Phase 3 N=207 Extended Varenicline Treatment for Smoking Among Cancer Patients
Nicotine Dependence
Primary: 7-day CO-verified Tobacco Abstinence — 28; 32; 16; 17 participants
Phase 3 N=718 Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Open-angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) — 24.84; 24.81; 24.59; 23.72 mmHg — p=<0.0001
Phase 3 N=432 A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas
Leiomyoma · Uterine Hemorrhage
Primary: Percentage of Participants With Absence of Bleeding During the Last 35 Consecutive Days on Treatment in Treatment Course 1 — 0.0; 42.0; 54.8 percentage of participants
Phase 3 N=50 Intravenous Fluid Therapy for the Treatment of Emergency Department Patients With Migraine Headache
Migraine Headache
Primary: Verbal Pain Score at 60 Minutes — 4.5; 4.9 units on a scale (0-10)
Phase 3 N=481 Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis
Erosive Esophagitis
Primary: Percentage of Participants With Endoscopic Healing of Erosive Esophagitis During the 8-Week Treatment Phase — 92.4; 91.3 percentage of participants